Regulatory Senior Group Director, Roche
Executive Director, Tufts Center for the Study of Drug Development
Senior R&D Productivity and Transformation Manager, Lundbeck
Executive Director, IQVIA Institute for Human Data Science
Director of R&D Research, IQVIA Institute for Human Data Science
Industry end-to-end clinical development duration reached a median of 10 years in 2025, as described in the IQVIA Institute’s Global R&D Trends 2026 report, with enrollment duration, overall trial duration, and between-trial intervals acting as brakes on R&D efficiency. However, sponsors are employing a variety of process- and technology-based enablers in their efforts to improve speed and overall efficiency. In parallel, regulatory agencies are innovating to improve review timelines, reduce sponsor burden, and enhance country or regional competitiveness. In this webinar, we will review recent cycle time findings from the 2026 report and discuss opportunities to accelerate R&D.
The 1.5h webinar will start with a short presentation from the Institute on relevant highlights from our report, followed by a moderated discussion among panellists and with time included for Q&A submitted by the audience.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
Discover unrealized connections and manage your product across the entire lifecycle, from research and development, compliance to launch and commercialization.
.svg){kind=icon}
